Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
0.9200
+0.0049 (0.54%)
Oct 27, 2026, 4:00 PM EDT - Market closed
Allarity Therapeutics Revenue
Allarity Therapeutics had revenue of $345.00K in the twelve months ending June 30, 2026. In the year 2025, Allarity Therapeutics had annual revenue of $320.00K. That makes Allarity Therapeutics the 44,937th largest company in the world by revenue and 6,453rd in the United States.
Revenue (ttm)
$345.00K
Revenue Growth
n/a
P/S Ratio
42.43
Revenue / Employee
$43,125
Employees
8
Market Cap
14.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 320.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Radiopharm Theranostics | 8.90M |
| TScan Therapeutics | 7.11M |
| SeaStar Medical Holding | 1.71M |
| Pluri | 1.02M |
| aTyr Pharma | 190.00K |
| Vyome Holdings | 129.73K |
| Kiora Pharmaceuticals | 20.00K |
| BioCardia | 3.00K |
ALLR News
- 27 days ago - Allarity updates on recent advances in Drug Response Predictor technology - TheFly
- 27 days ago - Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development - GlobeNewsWire
- 4 weeks ago - Allarity expands lab capabilities to include proteomics, cell line research - TheFly
- 4 weeks ago - Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research - GlobeNewsWire
- 6 weeks ago - Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development - GlobeNewsWire
- 6 weeks ago - Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - GlobeNewsWire
- 3 months ago - Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - GlobeNewsWire